GHK-Cu.99% cu50 cu100

Product Product Name: Retatrutide k Delivery: Ships immediately after payment received Regular packing: 5mg/vial, 10mg/vial, 15mg/vial, 20mg/vial, 30mg/vial Retatrutide is a novel triple agonist of GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulin-stimulating peptide) and glucagon receptor. As a multi-target hypoglycemic drug, it significantly improves blood glucose control, promotes weight loss, and may bring multiple benefits to cardiovascular metabolism by simultaneously activating three enteroinsulin-stimulating receptors. Mechanism of Action Exert a combined effect by activating three receptors: 1.GLP-1 receptor: Enhances insulin secretion, inhibits glucagon, delays gastric emptying, and increases satiety. 2.GIP receptor: Improves insulin sensitivity and regulates energy metabolism. 3.Glucagon receptor: Promotes fat breakdown and increases energy expenditure. Product advantages 1.Triple excitation mechanism: Simultaneously activate GLP-1, GIP and glucagon receptors to synergistically regulate metabolism. 2.Highly effective hypoglycemic effect: Significantly reduces the blood glucose level (HbA1c) of patients with type 2 diabetes mellitus (T2DM). 3.Significant weight loss: Clinical data show that the weight loss effect is superior to that of single/double receptor agonists (such as semaglutide and tielpotide). 4.Comprehensive improvement of metabolism: Potential benefits include lowering blood lipids, improving fatty liver and providing cardiovascular protection. Our Advantages High quality, competitive price, adequate stock and fast delivery competitive price.

Shanghai TL-output Peptide Technology Co., Ltd China and is recognized as a high-tech enterprise providing technical consulting and testing services for novel chemical compounds.


The company’s internal quality control standards consistently exceed national regulatory requirements, and a comprehensive quality assurance system has been firmly established. Over 60% of our products are exported overseas, with primary markets including Europe, the Americas, Australia, Russia, Japan, South Korea, as well as various countries and regions across Southeast Asia.

The company maintains a 1,000-square-meter R&D and pilot-scale production facility, equipped with a wide array of modern laboratory research instruments. This facility enables us to conduct small-scale research and pilot production for a diverse range of chemical compounds. Furthermore, the company operates a collaborative production base spanning 30 *mu* (approximately 2 hectares), outfitted with a complete suite of large-scale stainless steel and glass-lined production equipment. With reactor capacities ranging from 50 to 2,000 liters, the facility possesses the capability to handle R&D and production at the ton scale.

Shanghai TL-output Peptide Technology Co., Ltd. is supported by a highly organized team, experienced technical personnel, and expert chemists specializing in R&D and quality control—assets that enable us to consistently deliver high-quality products. We collaborate with numerous renowned domestic and international scientific research institutions, providing professional services and superior products; our custom synthesis services, in particular, have earned us an excellent reputation within the industry.


Upholding the core philosophy of "Green and Healthy," Shanghai TL-output Peptide Technology Co., Ltd. sincerely looks forward to strengthening exchanges and cooperation with partners and friends both at home and abroad.